RANDOMIZED, OPEN LABEL, PARALLEL-GROUP, TWO-ARM, MULTICENTER STUDY WITH CLINICAL ENDPOINT COMPARING PRESERVATIVE FREE BIMATOPROST OPHTHALMIC SOLUTION 0.1 MG/ML AND LUMIGAN® (BIMATOPROST OPHTHALMIC SOLUTION) 0.1 MG/ML IN PATIENTS WITH CHRONIC OPEN-ANGLE GLAUCOMA OR OCULAR HYPERTENSION IN ONE OR BOTH EYES. - BIM-001

Start Date11 Apr 2024

Sponsor / Collaborator

Genetic SpA

NCT06267274

/ RecruitingPhase 1

A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint Comparing Generic Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® (Bimatoprost Ophthalmic Solution) 0.01% in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes

A randomized, double-blind, parallel-group, two-arm, multiple dose, multicenter, clinical endpoint bioequivalence study

Start Date01 Apr 2024

Sponsor / Collaborator

Amneal Intermediate, Inc.

[+1]

100 Clinical Results associated with Bimatoprost

100 Translational Medicine associated with Bimatoprost

100 Patents (Medical) associated with Bimatoprost

1,129

Literatures (Medical) associated with Bimatoprost

01 May 2025·European Journal of Pharmacology

Treatment of glaucoma with drug-loaded contact lenses: A systematic review and meta-analysis

Review

Author: Xu, Zihang ; Yu, Mingkun ; Wang, Xuan ; Ren, Cong ; Cao, Wenbo ; Zhang, Diya ; Guo, Bin ; Li, Jia ; Bi, Hongsheng

OBJECTIVEThis study is a systematical review regarding the glaucoma treatment with drug-loaded contact lenses. The effectiveness and safety about that were summarized, which providing effective suggestions and guidance for clinical research.METHODSThe studies published up to May 1, 2024 on the treatment of glaucoma with sustained-release contact lenses were searched from CNKI, Wanfang Data, VIP, PubMed, Embase, Cochrane Library, and Medline. CAMARADES was used to evaluate literature quality. The safety, endpoints of intraocular pressure reduction (IOPR) and duration of intraocular pressure (IOP) decline during glaucoma treatment were analyzed by means of qualitative and quantitative methods. The protocol registration number is CRD42024487157.RESULTS47 studies were included. In clinical trials, glaucoma patients showed a 50% reduction in IOP and no corneal tissue destruction after wearing contact lenses. In animal experiments, the endpoint IOPR [MD = 0.58, 95%CI (0.37, 0.80), P < 0.00001] of the medicated contact lenses group was significantly better than that of the eye drops group. Subgroup analysis showed that contact lenses loaded with timolol (TML), with TML + dorzolamide, and with TML + latanoprost, which compared to eye drops, had a better effect on reducing IOP, while contact lenses loaded with puerarin, latanoprost, and TML + bimatoprost showed no statistical difference. Most studies demonstrated the duration of IOP reduction and drugs release in vitro for ≥3 days during contact lenses treatment.CONCLUSIONMost drug-loaded contact lenses exhibit excellent effectiveness and safety. The nanoparticle-loaded contact lenses containing TML for glaucoma treatment is recommended in future clinical research.

01 Apr 2025·American Journal of Ophthalmology

Phase 3, Randomized, Comparison Study of Intracameral Bimatoprost Implant 10 µg and Selective Laser Trabeculoplasty

Article

Author: Robinson, Michael R ; Shiu, Michael ; Paauw, James D ; Tatham, Andrew J ; Kim, Kimmie ; Uy, Harvey S ; Jiao, Jenny ; Lim, Kin Sheng ; Ho, Quoc ; Goodkin, Margot L ; Bejanian, Marina ; Kolko, Miriam ; Wells, Anthony P ; Sarkisian, Steven R

PURPOSETo evaluate the intraocular pressure (IOP)-lowering effect and safety of up to 2 bimatoprost implant administrations versus selective laser trabeculoplasty (SLT).DESIGNPhase 3 (Stage 2), randomized, 24-month, multicenter, patient- and efficacy evaluator-masked, paired-eye clinical trial (NCT02507687).PARTICIPANTSPatients (n = 183) with open-angle glaucoma or ocular hypertension inadequately managed with topical IOP-lowering medication for reasons other than efficacy.INTERVENTIONPatients received a single 360° SLT procedure in 1 eye and 10-µg bimatoprost implant administration in the contralateral eye. Initially, implant-treated eyes received a second implant at week 16 if safety criteria were met. After a protocol amendment, implant-treated eyes were retreated with flexible scheduling if IOP was >17 mm Hg and safety criteria were met.MAIN OUTCOME MEASURESThe primary efficacy variable was IOP change from baseline, with primary timepoints at weeks 4, 12, and 24. Safety measures included treatment-emergent adverse events (TEAEs) and ocular safety measures.RESULTSMean (±SE) baseline IOP (mm Hg) was 25.2 ± 0.22 and 25.1 ± 0.22 in implant- and SLT-treated eyes, respectively. Least-squares mean (±SE) IOP reduction from baseline (mm Hg) for eyes treated with up to 2 implants versus SLT was 6.8 ± 0.28 versus 6.2 ± 0.28 at week 4, 6.9 ± 0.30 versus 6.4 ± 0.30 at week 12, and 6.9 ± 0.27 versus 6.5 ± 0.28 at week 24. The probability of not having required nonstudy (rescue) IOP-lowering treatment at days 360 and 720, respectively, was 67.5% and 50.2% for implant-treated eyes versus 68.7% and 60.6% for SLT-treated eyes. The most common ocular TEAE in both implant- and SLT-treated eyes was increased IOP attributed to wearing off of efficacy. Mean (±SE) percentage change in corneal endothelial cell density from baseline at month 24 was -6.2 ± 1.13% in implant-treated eyes (-7.9 ± 2.04% with fixed readministration; -5.2 ± 1.35% with flexible readministration) versus -3.1 ± 0.43% in SLT-treated eyes.CONCLUSIONSThe bimatoprost implant demonstrated statistical and clinical noninferiority to SLT in IOP reduction from baseline at weeks 4, 12, and 24. In subgroup analysis, patients with flexible implant readministration met the same criteria. Both the implant and SLT demonstrated sustained (2-year) IOP lowering in many eyes. A flexible administration schedule improved the safety profile of the implant over the fixed administration schedule.

01 Mar 2025·Current Opinion in Ophthalmology

New treatments for glaucoma

Article

Author: Mai, Anthony P. ; Ferguson, Tanner J. ; Radcliffe, Nathan

Purpose of reviewThis review highlights new Federal Drug Administration (FDA) approved glaucoma treatments to familiarize providers with immediately available options.Recent findingsNew FDA-approved treatments include the bimatoprost implant, travoprost implant, direct selective laser trabeculoplasty (DSLT), and ocular pressure adjusting pump. The bimatoprost implant is approved for a single administration with effects lasting for about 1 year, as opposed to the nearly 3-year effect for the travoprost implant. Meanwhile, the DSLT lowers intraocular pressure (IOP) by applying a laser through the limbus within 2 s. Lastly, the ocular pressure adjusting pump is a noninvasive, nonpharmaceutical device that lowers IOP with negative pressure within a pair of goggles. Not only do these modalities lower IOP, but they also improve the patient experience by reducing drop burden, decreasing laser duration, or lowering side effects. Although the list of therapies still in development is extensive, another two promising devices under review include a supraciliary stent and an adjustable aqueous tube shunt.SummaryGlaucoma treatment has considerably evolved over the last decade with the introduction of novel topical medications, minimally invasive glaucoma surgeries, sustained-release drug delivery systems, and wearable devices. This expansion in glaucoma has enabled more patient-centric decision-making regarding treatment.

News (Medical) associated with Bimatoprost

06 Feb 2025

·www.businesswire.com

MediPrint Ophthalmics Advances Glaucoma Program, Expands Patent Portfolio, and Prepares for Key Industry Presentation

SAN DIEGO--( BUSINESS WIRE )--MediPrint® Ophthalmics, a clinical-stage ophthalmic drug delivery company, continues to advance its innovative glaucoma program following the successful completion of its Phase 2b clinical trial for LL-BMT1. As the company progresses towards the next phase of development, MediPrint anticipates meeting with the U.S. Food and Drug Administration (FDA) in 2025 to discuss preparations for Phase 3 clinical studies. Regulatory Progress and Path Toward Phase 3 Following the promising results from its Phase 2b trial, MediPrint remains committed to bringing LL-BMT1 to market as a novel drug delivery platform for the treatment of glaucoma and ocular hypertension. The company expects to engage with the FDA in 2025 to align regulatory requirements and define the pathway for Phase 3 studies. LL-BMT1’s sustained drug delivery approach via a 3D-printed, drug-eluting contact lens offers a potential paradigm shift in glaucoma care by significantly reducing treatment burden and enhancing patient compliance. The study demonstrated that LL-BMT1 provided similar therapeutic results as a once-a-week solution to the comparator, 0.01% bimatoprost eye drop, offering a significant dosing advantage over one or multiple-times-per-day eye drop regimens. Expansion of Patent Portfolio: Extending Innovation and Leadership MediPrint has further solidified its intellectual property portfolio with the recent issuance of U.S. Patent No. 12,178,904 by the U.S. Patent and Trademark Office on December 31, 2024. This patent, which covers MediPrint’s proprietary chemistry related to the sustained delivery of prostaglandins from contact lenses, extends the company’s patent protection through 2043. The prostaglandin evaluated in LL-BMT1 was bimatoprost, a well-established treatment for lowering intraocular pressure in glaucoma patients. With this milestone, MediPrint’s global patent portfolio now encompasses 29 granted patents, with additional patents pending. This robust intellectual property estate reinforces the company’s leadership in ophthalmic drug delivery and underscores its commitment to pioneering innovative solutions for the treatment of ocular diseases. Upcoming Presentation at Glaucoma 360 New Horizons Forum MediPrint is also pleased to announce its participation in the upcoming Glaucoma Research Foundation’s annual meeting, the Glaucoma 360 New Horizons Forum, taking place this week in San Francisco. The company will present its latest developments in sustained drug delivery technology and discuss how LL-BMT1 could redefine the standard of care for patients with glaucoma. “ Our continued progress in both clinical development and intellectual property expansion reflects MediPrint’s unwavering commitment to innovation in ophthalmic drug delivery,” said Praful Doshi, Founder and CEO of MediPrint Ophthalmics. “ As we prepare for regulatory discussions and advance towards Phase 3, we remain focused on delivering transformative solutions that improve patient outcomes.” About MediPrint® Ophthalmics MediPrint® Ophthalmics is a San Diego-based clinical-stage eye care pharmaceutical company dedicated to enhancing vision for life. The company is pioneering drug-eluting contact lenses that deliver therapeutics directly to the eye, providing comfortable, convenient, preservative-free alternatives to traditional eye drop treatments. MediPrint’s portfolio is designed to address major eye conditions, including glaucoma, myopia, dry eye, and discomfort associated with contact lens use. For more information, please visit www.mediprintlens.com .

Clinical ResultPhase 2Phase 1Phase 3

28 Jan 2025

·www.globenewswire.com

Nicox Announces Scientific Presentation and Conference Attendance in H1 2025

Press Release Nicox Announces Scientific Presentation and Conference Attendance in H1 2025January 28, 2025 – release at 7:30 am CETSophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced a presentation at the upcoming American Glaucoma Society (AGS) Annual Meeting 2025 and participation in a number of key ophthalmology and financial conferences in the first half of 2025. Presentation of additional analysis of the NCX 470 Mont Blanc Phase 3 Clinical trial AGS 2025 Annual Meeting – February 26 to March 2, 2025, Washington, U.S. Poster Title: Diurnal Intraocular Pressure Control Responder Analysis with NCX 470 Versus Latanoprost in the Phase 3 MONT BLANC TrialType: Poster Presentation Session Date: Saturday March 1, 2025 from 7:00 am to 8:00 am (local time). Presenter: Dr. Robert Fechtner, Chair of the Department of Ophthalmology at SUNY Upstate Medical University in Syracuse, NY Upcoming Conference Attendance Allinvest securities Biomed Forum – February 4, 2025 – Paris, France Investor Access – April 1-2, 2025 – Paris, France Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting – May 4-8, 2025 – Salt Lake City, Utah, U.S.BIO International Convention – June 16-19, 2025 – Boston, MA, U.S. Members of the management team will be available for one-on-one meetings at these events. About NicoxNicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox’s lead program in clinical development is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox also has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos. Nicox’s first product, VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, is available commercially in the U.S. and over 15 other territories. Nicox generates revenue from ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the U.S., and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets. Nicox, headquartered in Sophia Antipolis, France, is listed on Euronext Growth Paris (Ticker symbol: ALCOX) and is part of the CAC Healthcare index. For more information www.nicox.com Analyst coverageH.C. Wainwright & Co Yi Chen New York, U.S. The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports. Contacts NicoxGavin SpencerChief Executive OfficerT +33 (0)4 97 24 53 00communications@nicox.com DisclaimerThe information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.Risks factors which are likely to have a material effect on Nicox’s business are presented in section 3 of the “Rapport Annuel 2023” and in section 4 of the “Rapport semestriel financier et d’activité 2024” which are available on Nicox’s website (www.nicox.com).Finally, this press release may be drafted in the French and English languages. If both versions are interpreted differently, the French language version shall prevail.Nicox S.A.Sundesk Sophia Antipolis, Bâtiment C, Emerald Square, Rue Evariste Galois, 06410 Biot, FranceT +33 (0)4 97 24 53 00 Attachment EN_H1_2025_CONFERENCES_PR_FINAL

Phase 3

21 Jan 2025

·www.globenewswire.com

Nicox Provides Business Update and Fourth Quarter 2024 Financial Highlights

Press Release Nicox Provides Business Update and Fourth Quarter 2024 Financial Highlights Last patient recruited in the NCX 470 (bimatoprost grenod) Phase 3 Denali clinical trial with topline results expected in Q3 2025 Fourth quarter 2024 Nicox Group revenue of €13.7 million Cash of €10.7 million as of December 31, 2024, following a €5.2 million debt repayment, which the Company estimates will finance it into the third quarter of 2025 January 21, 2025 – release at 7:30 am CETSophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today provided financial and business highlights for the fourth quarter of 2024 for Nicox SA and its subsidiaries (the “Nicox Group”). The Company does not report consolidated financial statements but discloses Nicox Group figures for information purposes only.“The final patient was enrolled into the Denali clinical trial in the last days of 2024 and we are therefore starting the year fully financed to complete this pivotal trial, with the results expected to be announced in the third quarter. Having maintained our timelines and stabilised our financial situation in the last 12 months, we are now focussing on the future direction of the company and the partnerships for the commercialization of NCX 470 in key territories outside of our collaborations with Ocumension and Kowa, principally the United States.” said Gavin Spencer, Chief Executive Officer of Nicox. Revenue, Cash Position for the Nicox Group for the Fourth Quarter 2024 and post-period events The last patient in the NCX 470 Denali Phase 3 trial has been recruited and topline results remain expected in Q3 2025.Nicox Group revenue for the fourth quarter of 2024 was €13.7 million, almost entirely consisting of proceeds from the sale of the VYZULTA royalty. Due to the sale of the VYZULTA royalty the Nicox Group received no material royalty revenue in the fourth quarter of 2024, compared1 to €2.2 million for the fourth quarter 2023, consisting entirely of royalty revenue. The accounting treatment of the proceeds from the sale of the VYZULTA royalty has not yet been determined. The Nicox Group had cash of €10.7 million at 31 December compared to €19.7 million at 30 September 2024 (including the estimated net proceeds from the VYZULTA royalty sale and accompanying investment in October 2024). The significant cash consumption is due to the partial repayment of the Company’s principal debt, set out below. Based on this cash position and expected milestone income from existing agreements the Company estimates that it is financed into the third quarter of 2025, including the topline results from the Denali trial. If any of the assumptions around estimated income or costs change, this may impact the cash runway of the Company and the ability to complete the Denali clinical trial.As of December 31, 2024, the Nicox Group had financial debt of €15.1 million (entirely held by Nicox SA), consisting of €14.2 million in the form of a bond financing agreement with Kreos Capital (an affiliate of BlackRock), and a €0.9 million credit agreement guaranteed by the French State, and granted in the context of the COVID-19 pandemic. Nicox repaid €5.2 million of the Kreos Capital debt following the sale of the VYZULTA royalty in October 2024. The Company continues to evaluate all options for non-dilutive and dilutive financing to extend its cash runway. In particular, the Company is actively exploring multiple strategic options which could facilitate the development and commercialization of its product candidate NCX 470 and the future growth of the Company. Key Future Milestones Whistler Phase 3b clinical trial, initiated in December 2023, investigating NCX 470’s dual mechanism of action (nitric oxide and prostaglandin analog) in intraocular pressure lowering: results are currently expected in the first quarter of 2025.  Denali Phase 3 clinical trial evaluating NCX 470 in patients with open-angle glaucoma or ocular hypertension: The last patient has been recruited and topline results are expected in Q3 2025.  All figures in this press release are non-audited. About NicoxNicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox’s lead program in clinical development is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Nicox also has a preclinical research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos. Nicox’s first product, VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, is available commercially in the U.S. and over 15 other territories. Nicox generates revenue from ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the U.S., and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets. Nicox, headquartered in Sophia Antipolis, France, is listed on Euronext Growth Paris (Ticker symbol: ALCOX) and is part of the CAC Healthcare index. For more information www.nicox.comAnalyst coverageH.C. Wainwright & Co Yi Chen New York, U.S. The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports. Contacts NicoxGavin SpencerChief Executive OfficerT +33 (0)4 97 24 53 00communications@nicox.com DisclaimerThe information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.Risks factors which are likely to have a material effect on Nicox’s business are presented in section 3 of the “Rapport Annuel 2023” and in section 4 of the “Rapport semestriel financier et d’activité 2024” which are available on Nicox’s website (www.nicox.com).Finally, this press release may be drafted in the French and English languages. If both versions are interpreted differently, the French language version shall prevail.Nicox S.A.Sundesk Sophia Antipolis, Bâtiment C, Emerald Square, Rue Evariste Galois, 06410 Biot, FranceT +33 (0)4 97 24 53 00 1 Revenue has previously been reported as net of royalty payments made by Nicox, which applied only to VYZULTA revenue. Following the sale of the VYZULTA revenue, Nicox will report only the gross revenue figures. Attachment EN_FY2024Q42024_PR_January 21 2025_FINAL

Financial StatementPhase 3

100 Deals associated with Bimatoprost

External Link

KEGG	Wiki	ATC	Drug Bank
D02724	Bimatoprost	S01EE03	DB00905

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Glaucoma	Japan	Senju Pharmaceutical Co., Ltd.	07 Jul 2009
Glaucoma	Japan	Takeda Pharmaceutical Co., Ltd.	07 Jul 2009
Hypotrichosis	United States	AbbVie, Inc.	24 Dec 2008
Glaucoma, Open-Angle	United States	AbbVie, Inc.	16 Mar 2001
Ocular Hypertension	United States	AbbVie, Inc.	16 Mar 2001

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Cataract	Phase 2	United States	SpyGlass Pharma IncStartup	13 Oct 2023
Glaucoma	Phase 1	United States	Allergan UC	01 May 2010
Glaucoma, Open-Angle	Discovery	Taiwan Province	Allergan UC	15 Dec 2014
Glaucoma, Open-Angle	Discovery	Malaysia	Allergan UC	15 Dec 2014
Alopecia, Male Pattern	Discovery	United States	Allergan UC	01 Aug 2013
Alopecia	Discovery	Germany	Allergan UC	01 Jun 2011
Alopecia	Discovery	United States	Allergan UC	01 Jun 2011
Androgenetic Alopecia	Discovery	Germany	Allergan UC	01 Jun 2011
Androgenetic Alopecia	Discovery	United States	Allergan UC	01 Jun 2011
Hypotrichosis	Discovery	United Kingdom	Allergan UC	01 Aug 2009

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04747808 (BusinessWire) Manual	Phase 2	Glaucoma	-	LL-BMT1 32-µg dose	(awtxohmjqa) = vufojoxjpf agarxliwua (obvkvczjsl ) View more	Positive	12 Nov 2024
				bimatoprost 0.01%	-
NCT03825380 (CTgov)	Phase 3	Glaucoma	485	Bimatoprost (T4032)	aagjjzopwl(lunhjalibv) = jgqrcykmvg oxoivfphvb (rwjqwegglk, coxvmtnqsm - sthjzjqxms) View more	-	21 Nov 2023
				Lumigan® (Lumigan®)	aagjjzopwl(lunhjalibv) = svorhvgfaj oxoivfphvb (rwjqwegglk, arvoejttut - zfoxlqcxek) View more
NCT04285580 (CTgov)	Phase 3	Glaucoma, Open-Angle	37	Bimatoprost SR (Bimatoprost SR 10 μg)	whrcugrzcd(brptofuexb) = bdaxiwlrga dvlaqajgfo (evcwbhedzr, izizbntxud - chthwgxooy) View more	-	08 Jun 2023
				LUMIGAN (LUMIGAN 0.01%)	whrcugrzcd(brptofuexb) = vlprqoxpqg dvlaqajgfo (evcwbhedzr, sozbbamems - izofnulvfh) View more
ARVO2023	Not Applicable	Oxygen radical damage	-	NCX 470 (0.1% bid)	aoybhawjkm(kxnujcqcla) = mgzkcjfqqv zycpkhokbl (zdbslfqwdk )	-	23 Apr 2023
				Lumigan® (bimatoprost 0.01%, ophthalmic solution)	aoybhawjkm(kxnujcqcla) = zcmudnlcvl zycpkhokbl (zdbslfqwdk )
NCT01157364 \| NCT02250651 \| NCT02247804 (Pubmed)	Phase 3	Ocular Hypertension \| Glaucoma, Open-Angle	-	Bimatoprost implant 10 µg	uoqnrauewe(kwyxdlbwct) = dlphpepttu tqapuigpxt (ivnajskadu )	-	28 May 2022
				Topical timolol maleate 0.5%	uoqnrauewe(kwyxdlbwct) = lhgfodqbmw tqapuigpxt (ivnajskadu )
NCT04747808 (CTgov)	Phase 2	Glaucoma, Open-Angle \| Ocular Hypotension	5	LL-BMT1	gcemqirili(yhxuduuclk) = tjvhevbipm lukhdllilb (xowlbblfwh, qhyrsjzauv - ubfsptebkx) View more	-	10 May 2022
NCT03850782 (Phase 3b Study, ARVO2022)	Phase 3	Ocular Hypotension	203	Bimatoprost implant	(tehczzystw) = iwezulvbvs mbikbmfdis (hkazqalqsk )	-	01 May 2022
NCT03891446 (PO080, AAO2021)	Phase 3	Glaucoma, Open-Angle	200	Bimatoprost implant 10μg	(tbvcxsqnuz) = igyjpdbwpg zvspgqmukr (lrhdhmciby, 3.6)	Positive	13 Nov 2021
				Bimatoprost implant 15μg	(tbvcxsqnuz) = ulairrgvwh zvspgqmukr (lrhdhmciby, 3.2)
NCT02250651 (CTgov)	Phase 3	Glaucoma, Open-Angle	528	Timolol Vehicle (placebo)+Active Comparator: Timolol 0.5%+Bimatoprost SR (Bimatoprost SR 15 μg)	faqzdguhaq(cvnralslqr) = ybvsfcgtbh uayxwoegwg (cbvxfirfvx, qsffmlkywi - wimsaohtrp) View more	-	28 Jul 2021
				Timolol Vehicle (placebo)+Active Comparator: Timolol 0.5%+Bimatoprost SR (Bimatoprost SR 10 μg)	faqzdguhaq(cvnralslqr) = qngksurubo uayxwoegwg (cbvxfirfvx, assgviiozm - veyrcyldto) View more
NCT02250651 \| NCT02247804 (ARVO2021)	Phase 3	-	230	Bimatoprost implant 10 µg	xgbtcvlnoi(vkiwqdchpk) = ekgpbzoqqm taqcmnffqu (zmuxpbulxy ) View more	-	01 Jun 2021

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Bimatoprost

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation